Sort by

Send to

Choose Destination

Links from PubMed

Items: 4


Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.

Landgren O, Gilbert ES, Rizzo JD, SociƩ G, Banks PM, Sobocinski KA, Horowitz MM, Jaffe ES, Kingma DW, Travis LB, Flowers ME, Martin PJ, Deeg HJ, Curtis RE.

Blood. 2009 May 14;113(20):4992-5001. doi: 10.1182/blood-2008-09-178046. Epub 2009 Mar 5.


B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome.

Gross TG, Steinbuch M, DeFor T, Shapiro RS, McGlave P, Ramsay NK, Wagner JE, Filipovich AH.

Bone Marrow Transplant. 1999 Feb;23(3):251-8. Review.


Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation.

Wagner HJ, Rooney CM, Heslop HE.

Biol Blood Marrow Transplant. 2002;8(1):1-8. Review.


Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient.

Spencer A, Szydlo RM, Brookes PA, Kaminski E, Rule S, van Rhee F, Ward KN, Hale G, Waldmann H, Hows JM, Batchelor JR, Goldman JM.

Blood. 1995 Nov 1;86(9):3590-7. Review.

Supplemental Content

Support Center